KIWOOM 미국블록버스터바이오테크의약품+ (483030) holdings & weights
Per-holding contribution · concentration · sector skew — a deep read
Fund overview
This is a Korea-listed ETF from 키움투자자산운용.
Fund details
Fund overview
This is a Korea-listed ETF from 키움투자자산운용.
30 identified stocks · net exposure / NAV 99.78%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.
Weight and calculation basis
30 identified stocks · net exposure / NAV 99.78%. Display weights are normalized to 100%; calculations retain original exposures without an additional leverage multiplier. Cash and unallocated contracts are excluded from stock attribution.
Investor flows
Today's summary
On a constituent basis, KIWOOM 미국블록버스터바이오테크의약품+'s theoretical return is +0.08%p. Today's biggest hero is Argenx, contributing +0.08%p (return +4.09%). The biggest suspect dragging it down is Ascendis Pharma A/S, at +0.00%p.
Its top 10 holdings make up about 79.3% of the fund. The concentration index (HHI) is 736 — Low — evenly diversified, and the largest sector is Health Care (100%). The higher the concentration, the more one stock or sector drives the whole ETF's return.
Structural health
A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.
Concentration is below 1,500 (736), so no single holding dominates.
Health Care alone is 100%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.
A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.
We don't have cost, fund size for KIWOOM 미국블록버스터바이오테크의약품+ yet, so those axes are excluded and the score is based on the other 3. Scoring a missing figure as zero would grade our data collection, not the fund.
Concentration and diversification
Structural health
A five-axis read on how this fund is built. It is not a return forecast or a recommendation, and a low score does not mean a bad fund — leveraged products score low by design. Each axis shows the figure behind it.
Concentration is below 1,500 (736), so no single holding dominates.
Health Care alone is 100%. This is effectively a bet on that one industry — if the sector falls, diversification will not help.
A plain 1x physical fund holding the shares themselves — no structural drift from how long you hold it.
We don't have cost, fund size for KIWOOM 미국블록버스터바이오테크의약품+ yet, so those axes are excluded and the score is based on the other 3. Scoring a missing figure as zero would grade our data collection, not the fund.
Top 20 holdings
Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.
Normalized to 100% of analysed positions
Weights are normalized to 100% of absolute exposures across analysed positions, including positions outside this top list. Cash, collateral and unverified assets are excluded. Contributions retain original signed NAV exposures; leverage is not applied twice.
| # | Holding | Weight |
|---|---|---|
| 1 | MerckMRK | 10.81% |
| 2 | AbbVieABBV | 10.53% |
| 3 | Eli LillyLLY | 10.19% |
| 4 | Johnson & JohnsonJNJ | 9.42% |
| 5 | SanofiSNY | 9.02% |
| 6 | Novo Nordisk A/SNVO | 8.28% |
| 7 | AmgenAMGN | 7.32% |
| 8 | NovartisNVS | 5.06% |
| 9 | Bristol-Myers SquibbBMY | 4.78% |
| 10 | GSKGSK | 3.94% |
| 11 | PfizerPFE | 3.90% |
| 12 | Takeda PharmaceuticalTAK | 3.67% |
| 13 | ModernaMRNA | 2.91% |
| 14 | ArgenxARGX | 1.87% |
| 15 | Alnylam PharmaceuticalsALNY | 1.58% |
| 16 | Regeneron PharmaceuticalsREGN | 1.34% |
| 17 | Gilead SciencesGILD | 1.22% |
| 18 | BiogenBIIB | 0.65% |
| 19 | Genmab A/SGMAB | 0.47% |
| 20 | Ascendis Pharma A/SASND | 0.44% |
Holdings below 0.5% or outside the top list are folded into “Others” and omitted above.
Where the weight sits — sector mix
Listed equity weights summed by sector and normalized to 100%. Each band is one sector's share.
Industry breakdown
HHI sums the squared weights. The more it leans on a few names, the higher it goes — and the more the whole ETF moves with them.
How concentrated is it
Concentration (HHI) is low at 736, with the top 10 holdings at just 79.3% of equity weight. No single name can dominate the fund.
Good for damping single-stock risk — and equally, a big winner inside gets diluted.
HHI squares each weight and sums them: 10,000 means one stock is everything, and the more evenly spread the holdings, the closer it falls to zero.
Where the sector weight sits
By sector, Health Care alone is 100% — whatever the fund is called, this is a bet on that industry.
Bad news for the sector moves the whole fund. Worth checking against anything else you hold in the same space.
Weights above sum the individually listed equities and normalize that equity total to 100%.
How much it overlaps others
It shares 63% of its holdings with 497510 (13 names in common) — close to half the same companies.
Own both and the diversification is thinner than it looks.
What it is made of
The fund holds 31 positions in total; this page lists the largest 30 and folds the rest into "Others".
This page is not investment advice. Investment decisions and responsibility are your own.
483030 comments
Leave a one-line take on KIWOOM 미국블록버스터바이오테크의약품+. No account — just a nickname and a code to delete it later.
Loading…
Similar ETFs
Picked by how much their actual holdings overlap. The higher the overlap, the less diversification you get from owning both.